文献速递炎症性肠病肝病

硬化性胆管炎对炎症性肠病的保护作用

Protective function of sclerosing cholangitis on IBD.
PubMed 文献 · Gut · 2024-07-11

该研究在小鼠结肠炎和硬化性胆管炎模型中分析结肠炎严重程度,并在炎症性肠病(IBD)和PSC-IBD患者中评估Foxp3+调节性T细胞浸润及肠道菌群。结果显示硬化性胆管炎通过改变肠道菌群组成促进Foxp3+调节性T细胞扩增,从而减轻IBD;PSC-IBD患者结肠Foxp3表达增加且IBD严重程度总体较轻,PSC患者粪菌移植可保护小鼠免于结肠炎。

要点

  • 小鼠模型中硬化性胆管炎减轻结肠炎,依赖Foxp3+调节性T细胞扩增。
  • PSC-IBD患者结肠Foxp3表达增加,IBD严重程度总体较轻。
  • PSC患者肠道菌群移植可保护无菌小鼠免于结肠炎。

核心结论

  • 本研究显示原发性硬化性胆管炎(PSC)减轻IBD,并全面揭示其涉及的作用机制。

研究设计与样本

  • 研究分析实验性小鼠结肠炎和硬化性胆管炎模型以及IBD和PSC-IBD患者的结肠炎严重程度。
  • 通过qPCR和流式细胞术评估Foxp3+调节性T细胞浸润。
  • 对IBD、PSC-IBD患者及重现这些疾病的小鼠模型粪便样本进行菌群分析。
  • 将IBD和PSC-IBD患者的粪便菌群移植给无菌小鼠后诱导结肠炎。

主要发现

  • 小鼠模型中硬化性胆管炎减轻IBD。
  • 硬化性胆管炎改变肠道菌群组成,促进Foxp3+调节性T细胞扩增,从而预防IBD。
  • 在缺乏Foxp3+调节性T细胞时,硬化性胆管炎促进IBD。
  • PSC-IBD患者结肠Foxp3表达增加,IBD严重程度总体较轻。
  • 将PSC患者肠道菌群移植给无菌小鼠后,可保护其免于结肠炎。

关键数值与推荐

  • 约60%-80%的PSC患者会同时发生IBD(PSC-IBD)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a strong clinical association between IBD and primary sclerosing cholangitis (PSC), a chronic disease of the liver characterised by biliary inflammation that leads to strictures and fibrosis. Approximately 60%-80% of people with PSC will also develop IBD (PSC-IBD). One hypothesis explaining this association would be that PSC drives IBD. Therefore, our aim was to test this hypothesis and to decipher the underlying mechanism. DESIGN: Colitis severity was analysed in experimental mouse models of colitis and sclerosing cholangitis, and people with IBD and PSC-IBD. Foxp3+ Treg-cell infiltration was assessed by qPCR and flow cytometry. Microbiota profiling was carried out from faecal samples of people with IBD, PSC-IBD and mouse models recapitulating these diseases. Faecal microbiota samples collected from people with IBD and PSC-IBD were transplanted into germ-free mice followed by colitis induction. RESULTS: We show that sclerosing cholangitis attenuated IBD in mouse models. Mechanistically, sclerosing cholangitis causes an altered intestinal microbiota composition, which promotes Foxp3+ Treg-cell expansion, and thereby protects against IBD. Accordingly, sclerosing cholangitis promotes IBD in the absence of Foxp3+ Treg cells. Furthermore, people with PSC-IBD have an increased Foxp3+ expression in the colon and an overall milder IBD severity. Finally, by transplanting faecal microbiota into gnotobiotic mice, we showed that the intestinal microbiota of people with PSC protects against colitis. CONCLUSION: This study shows that PSC attenuates IBD and provides a comprehensive insight into the mechanisms involved in this effect.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Bedke T, Stumme F, Tomczak M, et al. Protective function of sclerosing cholangitis on IBD. Gut. 2024. PMID: 38839272. doi:10.1136/gutjnl-2023-330856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。